Cited 0 times in
Epidemiology of community-acquired pneumonia in the era of extended serotype-covering multivalent pneumococcal conjugate vaccines
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Heo, JY | - |
dc.contributor.author | Seo, YB | - |
dc.contributor.author | Jeong, HW | - |
dc.contributor.author | Choi, MJ | - |
dc.contributor.author | Min, KH | - |
dc.contributor.author | Choi, WS | - |
dc.contributor.author | Lee, J | - |
dc.contributor.author | Noh, JY | - |
dc.contributor.author | Cheong, HJ | - |
dc.contributor.author | Kim, WJ | - |
dc.contributor.author | Song, JY | - |
dc.date.accessioned | 2022-10-28T05:28:59Z | - |
dc.date.available | 2022-10-28T05:28:59Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 0264-410X | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/22490 | - |
dc.description.abstract | BACKGROUND: South Korea has been providing 10-valent pneumococcal conjugate vaccine/(PCV10)/13-valent pneumococcal conjugate vaccine (PCV13) to children and 23-valent pneumococcal polysaccharide vaccine (PPSV23) to older adults as part of a national immunization program.
METHODS: From September 2015 to August 2017, a prospective cohort study was conducted for adults aged >/=19 years with community-acquired pneumonia (CAP) at four university hospitals. All-cause and pneumococcal CAP incidence and mortality rates were evaluated on the basis of hospital catchment population. Serotype distribution of pneumococcal CAP was also evaluated. RESULTS: Among 2669 patients with CAP, 252 cases (9.4%) were pneumococcal CAP cases. The annual incidences of all-cause and pneumococcal CAP were 194.3 cases and 18.3 cases respectively, per 100,000 persons. Serotyped Streptococcus pneumoniae was identified in 107 cases (42.5%) through culture or a serotype-specific urinary antigen detection assay. Pneumococcal CAP caused by the PCV13 and PPSV23 serotypes were 50 cases (46.7% of serotyped pneumococcal CAP and 19.8% of pneumococcal CAP), and 83 cases (77.6% of serotyped pneumococcal CAP and 32.9% of pneumococcal CAP), respectively. The most prevalent serotype was 3 (n = 21, 19.6% of serotyped pneumococcal CAP), followed by 19A (n = 10, 9.3% of serotyped pneumococcal CAP) and 11A (n = 10, 9.3% of serotyped pneumococcal CAP). Compared with non-pneumococcal CAP patients, pneumococcal CAP patients were more likely to have a higher CURB-65 scores (P = 0.002). The overall 30-day mortality rate of pneumococcal CAP was higher than that of non-pneumococcal CAP (6.3% versus 5.6%; odds ratio [OR], 1.15; 95% confidence interval [CI], 0.67-1.96), but this trend was reversed in patients aged 65-74 years (4.2% versus 8.6%; OR, 0.47; 95% CI, 0.14-1.54). CONCLUSIONS: The disease burden of PCV13-serotype pneumococcal CAP remains significantly high in Korean adults, particularly among elderly people, even after a high uptake of pediatric PCVs. | - |
dc.language.iso | en | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Child | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Pneumococcal Infections | - |
dc.subject.MESH | Pneumococcal Vaccines | - |
dc.subject.MESH | Pneumonia, Pneumococcal | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Serogroup | - |
dc.subject.MESH | Vaccines, Conjugate | - |
dc.subject.MESH | Young Adult | - |
dc.title | Epidemiology of community-acquired pneumonia in the era of extended serotype-covering multivalent pneumococcal conjugate vaccines | - |
dc.type | Article | - |
dc.identifier.pmid | 33164798 | - |
dc.subject.keyword | Community-acquired pneumonia | - |
dc.subject.keyword | Epidemiology | - |
dc.subject.keyword | Incidence | - |
dc.subject.keyword | Mortality | - |
dc.subject.keyword | Pneumococcus | - |
dc.contributor.affiliatedAuthor | Heo, JY | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1016/j.vaccine.2020.10.046 | - |
dc.citation.title | Vaccine | - |
dc.citation.volume | 38 | - |
dc.citation.number | 49 | - |
dc.citation.date | 2020 | - |
dc.citation.startPage | 7747 | - |
dc.citation.endPage | 7755 | - |
dc.identifier.bibliographicCitation | Vaccine, 38(49). : 7747-7755, 2020 | - |
dc.embargo.liftdate | 9999-12-31 | - |
dc.embargo.terms | 9999-12-31 | - |
dc.identifier.eissn | 1873-2518 | - |
dc.relation.journalid | J00264410X | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.